Table 4.
Bivariate Relationships for Obesity and Covariates with Patient Reported Outcomes
| SLAQ | CES-D | SF-36 Pain | SF-36 Vitality | |
|---|---|---|---|---|
| β (P) | β (P) | β (P) | β (P) | |
| Body Composition | ||||
| Obese by FMI ≥ 13 kg/m2 | 4.55 (<0.001) | 7.74 (<0.001) | −7.16 (<0.001) | −6.98 (0.001) |
| Obese by BMI ≥ 30 kg/m2 | 4.54 (0.001) | 8.17 (<0.001) | −7.30 (<0.001) | −8.66 (<0.001) |
| Covariates | ||||
| Age | 0.02 (0.68) | −0.01 (0.90) | −0.07 (0.31) | −0.11 (0.17) |
| Race | −0.78 (0.55) | 2.76 (0.20) | 0.77 (0.68) | −2.91 (0.15) |
| Low education1 | 1.27 (0.48) | 2.67 (0.38) | −2.95 (0.26) | −2.90 (0.31) |
| Poverty level income2 | 4.26 (0.01) | 8.87 (0.001) | −5.49 (0.02) | −5.35 (0.04) |
| Smoking, current | 5.13 (0.04) | 2.18 (0.62) | −5.29 (0.16) | −2.15 (0.60) |
| Smoking, ever | 0.79 (0.53) | −1.01 (0.64) | −3.90 (0.04) | 0.23 (0.91) |
| Disease Duration | −0.09 (0.16) | −0.01 (0.90) | −0.05 (0.61) | 0.02 (0.81) |
| BILD Score | 0.57 (0.055) | 0.46 (0.36) | −1.22 (0.01) | −0.83 (0.08) |
| Prednisone Use (yes/no) | 2.20 (0.08) | 1.47 (0.49) | −3.31 (0.07) | −2.41 (0.23) |
| Prednisone Dose | 0.18 (0.08) | 0.09 (0.60) | −0.25 (0.10) | −0.04 (0.81) |
| Prednisone > 7.5 mg/day | 4.64 (0.002) | 4.20 (0.11) | −5.70 (0.01) | −2.92 (0.23) |
| Oral DMARD3 | −0.52 (0.69) | 2.16 (0.32) | −2.53 (0.18) | −4.80 (0.02) |
| Immunosuppression4 | −0.48 (0.70) | 3.23 (0.13) | −2.74 (0.14) | −5.13 (0.01) |
SLAQ, Systemic Lupus Activity Questionnaire; CES-D, Center for Epidemiologic Studies Depression Scale; SF-36 Pain, Short Form 36 Health Survey Pain Subscale (higher scores indicate less pain); SF-36 Vitality, Short Form 36 Vitality Subscale (higher scores indicate less fatigue); FMI, fat mass index; BMI, body mass index; BILD, Brief Index of Lupus Damage; DMARD, Disease-modifying antirheumatic drugs.
1
No education beyond high school.
2
Household income ≤ 125% of the federal poverty level.
3
Includes azathioprine, mycophenolate mofetil, methotrexate, and tacrolimus.
4
Includes oral DMARDs listed above plus cyclophosphamide and rituximab.